Risk-adapted treatment for patients with clinical stage I nonseminomatous germ cell tumor of the testis

Urology

Volumn 63, Issue 1, 2004, Pages 144-148

  Amato, Robert J ^a   Ro, Jae Y ^b   Ayala, Alberto G ^b   Swanson, David A ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BIOLOGICAL MARKER; BLEOMYCIN; CARBOPLATIN; ETOPOSIDE;

ARTICLE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CELL INVASION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG TOLERABILITY; EMBRYONAL CARCINOMA; FOLLOW UP; HEALTH CARE COST; HIGH RISK POPULATION; HUMAN; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; NONSEMINOMATOUS GERM CELL TUMOR; ORCHIECTOMY; PATIENT COMPLIANCE; PRIORITY JOURNAL; TERATOMA; TESTIS TUMOR; VESSEL;

EID: 0742306938     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urology.2003.08.045     Document Type: Article

References (27)

1. Donohue J.P., Thornhill J.A., Foster R.S., et al. Retroperitoneal lymphadenectomy for clinical stage I testis cancer (1965-1989) modifications of technique and impact on ejaculation . J Urol. 149:1993;237-243.
2. Raghavan D., Colls B., Levi J., et al. Surveillance for stage I nonseminomatous germ cell tumours of the testis the optimal protocol has not yet been defined . Br J Uro1. 61:1988;522-526.
3. Fung C.Y., Garnick M.B. Clinical stage I carcinoma of the testis a review . J Clin Oncol. 6:1988;734-750.
4. McLeod D.G., Weiss R.E., Stablein D.M., et al. Staging relationships and outcome in early stage testicular cancer a report from the Testicular Cancer Intergroup Study . J Urol. 145:1991;1178-1183.
5. Scher H.I., Sternberg C.N. Chemotherapy of urologic malignancies. Semin Uro1. 3:1985;239-280.
6. Sternberg C.N., Bosl G. Advances in testicular cancer role of chemotherapy . Prog Clin Biol Res. 277:1988;79-84.
7. Freedman L.S., Parkinson M.C., Jones W.G., et al. Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchidectomy alone. Lancet. 2:1987;294-298.
8. Fung C.Y., Kalish L.A., Brodsky G.L., et al. Stage I nonseminomatous germ cell testicular tumor prediction of metastatic potential by primary histopathology . J Clin Onco1. 6:1988;1467-1473.
9. Mead G.M., Stenning S.P., Parkinson M.C., et al. The second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors. J Clin Oncol. 10:1992;85-94.
10. Hesketh P.J., Krane R.J. Prognostic assessment in nonseminomatous testicular cancer implications for therapy . J Urol. 144:1990;1-9.
11. Dunphy C.H., Ayala A.G., Swanson D.A., et al. Clinical stage I nonseminomatous and mixed germ cell tumors of the testis. Cancer. 62:1988;1202-1206.
12. Wishnow K.I., Johnson D.E., Swanson D.A., et al. Identifying patients with low-risk clinical stage I nonseminomatous testicular tumors who should be treated by surveillance. Urology. 34:1989;339-343.
13. Sternberg C.N. Role of primary chemotherapy in stage I and low-volume stage II nonseminomatous germ-cell testis tumors. Urol Clin North Am. 20:1993;93-109.
14. Ansfield F.J., Korbitz B.C., Davis H.L. Jr, et al. Triple drug therapy in testicular tumors. Cancer. 24:1969;442-446.
15. Skinner D.G. Nonseminomatous testis tumors a plan of management based on 96 patients to improve survival in all stages by combined therapeutic modalities . J Urol. 115:1976;65-69.
16. Ekman E.P., Edsmyr F. Chemotherapy in nonseminomatous testicular tumours stage I. Br J Urol. 53:1981;184-187.
17. Sandeman T.F., Yang C. Results of adjuvant chemotherapy for low-stage nonseminomatous germ cell tumors of the testis with vascular invasion. Cancer. 62:1988;1471-1475.
18. Gimmi C., Sonntag R., Brunner K., et al. Adjuvant treatment of high-risk (HR) clinical stage I testicular carcinoma (TC) with cisplatin (C), bleomycin (B) and vinblastine (V) or etoposide (E). (abstract) Proc ASCO. 9:1990;140.
19. Pont J., Holtl W., Kosak D., et al. Risk-adapted treatment choice in stage I nonseminomatous testicular germ cell cancer by regarding vascular invasion in the primary tumor a prospective trial . J Clin Onco1. 8:1990;16-20.
20. Madej G., Pawinski A. Risk-related adjuvant chemotherapy for stage I non-seminoma of the testis. Clin Onco1. 3:1991;270-272.
21. Oliver R.T., Raja M.A., Ong J., et al. Pilot study to evaluate impact of a policy of adjuvant chemotherapy for high risk stage 1 malignant teratoma on overall relapse rate of stage 1 cancer patients. J Uro1. 148:1992;1453-1455.
22. Studer U.E., Fey M.F., Calderoni A., et al. Adjuvant chemotherapy after orchiectomy in high-risk patients with clinical stage I non-seminomatous testicular cancer. Eur Urol. 23:1993;444-449.
23. Cullen M.H., Stenning S.P., Parkinson M.C., et al. Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis a Medical Research Council report . J Clin Onco1. 14:1996;1106-1113.
24. Ravi R., Ong J., Oliver R.T.D. Long term follow-up of surveillance versus adjuvant chemotherapy treated stage I non-seminoma patients. (abstract) J Urol. 159:1998;49.
25. Bohlen D., Borner M., Sonntag R.W., et al. Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors. J Uro1. 161:1999;1148-1152.
26. Williams S.D., Stablein D.M., Einhorn L.H., et al. Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med. 317:1987;1433-1438.
27. Swanson D, von Eschenbach A, Babaian J, et al: Is retroperitoneal lymph node dissection (RLND) alone optimal or sufficient therapy for clinical stage I nonseminomatous germ cell testicular tumors (NSGCTT) at high risk for relapse (abstract)? J Urol 159(5 suppl): 49, 1998.